China Biologic Products Holdings Inc - Company Profile
Powered by 
All the sales intelligence you need on China Biologic Products Holdings Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how China Biologic Products Holdings Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with China Biologic Products Holdings Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
China Biologic Products Holdings Inc, a subsidiary of CBPO Holdings Ltd, is a biopharmaceutical company that focuses on research and development, production, commercialization of plasma-based products. The company is also involved in the sales of medical devices, mainly regenerative medical biomaterial products. The company’s products find application in medical emergencies and for the treatment and prevention of life threating and immune-deficiency related diseases. Few of the products of company include are Human Hepatitis B Immunoglobulin, Human Albumin, Placenta Polypeptide, and Artificial Dura Mater among others. It offers products to hospitals, other healthcare facilities in China and to distributors. China Biologic is headquartered in Beijing, China.
China Biologic Products Holdings Inc premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| Human Fibrinogen |
| Biopharmaceutical |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | China Biologic Products Holdings Inc | Shanghai RAAS Blood Products Co Ltd | China Resources Boya Bio-pharmaceutical Group Co Ltd | China National Biotec Group | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Beijing | Shanghai | Fuzhou | Beijing | Chengdu |
| State/Province | Beijing | Shanghai | Jiangxi | Beijing | Sichuan |
| No. of Employees | - | 4,045 | 1,947 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Li | Chairman | Executive Board | - | - |
| Andy Li | Chief Financial Officer | Senior Management | - | - |
| Wu Kun | President | Senior Management | - | - |
| Sun Bing | Chairman-Taibang Tianxinfu | Senior Management | - | - |
| Pang Guangli | Interim Chief Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer